Company: DVAX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001628280-25-049536
Chunk: 289

Company: DYNAVAX TECHNOLOGIES CORP
Filing Date: 2025-11-05
Form: 10-Q
Item: Part I, Item 8
Chunk 289
---
1):Cost of sales - product14,403 13,084 42,207 36,035 Research and development19,116 14,403 55,112 42,881 Selling and marketing21,791 23,902 70,199 73,701 General and administrative18,295 19,159 67,924 55,087 Other segment items (2)(5,656)(7,512)73,491 (22,749)Segment income (loss) (3)$26,927 $17,594 $(50,451)$20,259 (1)The significant expense categories and amounts align with the segment-level information that is regularly provided to the CODM.(2)Other segment items includes the net of: bad debt expense (Note 6), interest income, interest expense, sublease income (Note 5), loss on debt extinguishment (Note 7), other expenses, and provision for income taxes, as presented on the face of our condensed consolidated statements of operations.(3)Net income (loss) is our reported measure of segment profit or loss.

9. Revenue Recognition 

Disaggregation of RevenuesThe following table disaggregates our product revenue, net by product and geographic region and disaggregates our other revenues by geographic region (in thousands): Three Months EndedSeptember 30, 2025Three Months EndedSeptember 30, 2024 U.S.Non U.S.TotalU.S.Non U.S.TotalProduct revenue, net     HEPLISAV-B$89,954 $- $89,954 $79,345 $- $79,345 Total product revenue, net89,954 - 89,954 79,345 - 79,345 Other revenue4,739 183 4,922 1,263 22 1,285 Total revenues$94,693 $183 $94,876 $80,608 $22 $80,630 Nine Months EndedSeptember 30, 2025Nine Months EndedSeptember 30, 2024U.S.Non U.S.TotalU.S.Non U.S.TotalProduct revenue, netHEPLISAV-B$245,163 $1,622 $246,785 $195,030 $2,347 $197,377 Total product revenue, net245,163 1,622 246,785 195,